Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
scientific article published in March 2015
Author/s
author: Mitsune Tanimoto, Katsuyuki Kiura, Katsuyuki Hotta, Hiroshi Ueoka, Akihiro Bessho, Nagio Takigawa, Naoyuki Nogami, Toshiyuki Kozuki, Keisuke Aoe, Eiki Ichihara, Shoichi Kuyama, Kenichi Chikamori, Daizo Kishino, Shinobu Hosokawa, Toshio Kubo, Akiko Hisamoto-Sato, Daijiro Harada
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.